Status: Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
Participants needed: 220
Trial details
Phase: Phase 3Age: 18-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jun 1, 2026Locations: 18
Eligibility criteria
Signed informed consent must be obtained prior to participation in the OLE study... [+2]
Participants who prematurely withdrew from zigakibart parent studies in IgAN for... [+20]